

The Rule

This amendment to 14 CFR part 97 is effective upon publication of each separate SIAP and/or Weather Takeoff Minimums as contained in the transmittal. Some SIAP and/or Weather Takeoff Minimums amendments may have been previously issued by the FAA in a Flight Data Center (FDC) Notice to Airmen (NOTAM) as an emergency action of immediate flight safety relating directly to published aeronautical charts. The circumstances which created the need for some SIAP, and/or Weather Takeoff Minimums amendments may require making them effective in less than 30 days. For the remaining SIAPs and/or Weather Takeoff Minimums, an effective date at least 30 days after publication is provided.

Further, the SIAPs and/or Weather Takeoff Minimums contained in this amendment are based on the criteria contained in the U.S. Standard for Terminal Instrument Procedures (TERPS). In developing these SIAPs and/or Weather Takeoff Minimums, the TERPS criteria were applied to the conditions existing or anticipated at the affected airports. Because of the close and immediate relationship between these SIAPs and/or Weather Takeoff Minimums and safety in air commerce, I find that notice and public procedure before adopting these SIAPs and/or Weather Takeoff Minimums are impracticable and contrary to the public interest and, where applicable, that good cause exists for making some SIAPs and/or Weather Takeoff Minimums effective in less than 30 days.

Conclusion

The FAA has determined that this regulation only involves an established body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. It, therefore—(1) is not a “significant regulatory action” under Executive Order 12866; (2) is not a “significant rule” under DOT Regulatory Policies and Procedures (44 FR 11034; February 26, 1979); and (3) does not warrant preparation of a regulatory evaluation as the anticipated impact is so minimal. For the same reason, the FAA certifies that this amendment will not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 97

Air Traffic Control, Airports, Incorporation by reference, and Navigation (air).

Issued in Washington, DC on May 5, 2006.

James J. Ballough,

Director, Flight Standards Service.

Adoption of the Amendment

■ Accordingly, pursuant to the authority delegated to me, under Title 14, Code of Federal Regulations, Part 97 (14 CFR part 97) is amended by establishing, amending, suspending, or revoking Standard Instrument Approach Procedures and Weather Takeoff Minimums effective at 0901 UTC on the dates specified, as follows:

PART 97—STANDARD INSTRUMENT APPROACH PROCEDURES

■ 1. The authority citation for part 97 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40103, 40106, 40113, 40114, 40120, 44502, 44514, 44701, 44719, 44721–44722.

■ 2. Part 97 is amended to read as follows:

* * * *Effective 08 June 2006*

Magnolia, AR, Magnolia Muni, NDB RWY 36, Amdt 1, CANCELLED
Atlanta, GA, Hartsfield-Jackson Atlanta Intl, ILS OR LOC RWY 27R, Amdt 4
Pittsfield, MA, Pittsfield Muni, LOC RWY 26, Amdt 7

St. Louis, MO, Lambert St. Louis Intl, RNAV (GPS) RWY 11, Orig
St. Louis, MO, Lambert St. Louis Intl, RNAV (GPS) RWY 12L, Amdt 1
Cleveland, OH, Burke Lakefront, Takeoff Minimums and Textual DP, Amdt 4

* * * *Effective 03 August 2006*

Destin, FL, Destin-Fort Walton Beach, RADAR-1, Amdt 8, CANCELLED
Picayune, MS, Picayune Muni, NDB RWY 18, Orig, CANCELLED
Picayune, MS, Picayune Muni, NDB RWY 36, Orig, CANCELLED
St George, UT, St George Muni, RNAV (GPS) RWY 34, Amdt 1

[FR Doc. 06–4474 Filed 5–12–06; 8:45 am]

BILLING CODE 4910–13–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510 and 558

New Animal Drugs; Change of Sponsor

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendment.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for 25 approved new animal drug applications (NADAs) and 16 approved abbreviated new animal drug applications (ANADAs) for Type A medicated articles and feed use combinations from Intervet, Inc., to Huvepharma AD.

DATES: This rule is effective May 15, 2006.

FOR FURTHER INFORMATION CONTACT: David R. Newkirk, Center for Veterinary Medicine (HFV–100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–6967, e-mail: david.newkirk@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Intervet, Inc., P.O. Box 318, 29160 Intervet Lane, Millsboro, DE 19966, has informed FDA that it has transferred ownership of, and all rights and interest in, the following 25 approved NADAs and 16 approved ANADAs for Type A medicated articles and feed use combinations to Huvepharma AD, 33 James Boucher Blvd., Sophia 1407, Bulgaria:

Application No.	Trade Name(s)
NADA 044–759	FLAVOMYCIN (bambermycins) Type A medicated article
NADA 095–543	AMPROL HI-E / FLAVOMYCIN
NADA 095–547	AMPROL HI-E / FLAVOMYCIN / 3–NITRO
NADA 095–548	AMPROL / 3–NITRO / FLAVOMYCIN
NADA 095–549	AMPROL PLUS / 3–NITRO / FLAVOMYCIN
NADA 098–340	FLAVOMYCIN / MONENSIN
NADA 098–341	FLAVOMYCIN / 3–NITRO / COBAN
NADA 101–628	FLAVOMYCIN / 3–NITRO / ZOALENE
NADA 101–629	FLAVOMYCIN / ZOALENE
NADA 130–185	FLAVOMYCIN / AMPROLIUM
NADA 130–661	FLAVOMYCIN / CARB–O–SEP
NADA 130–951	STENOROL (halofuginone hydrobromide)

Application No.	Trade Name(s)
NADA 137-483	FLAVOMYCIN / STENOROL
NADA 139-473	STENOROL / STAFAC
NADA 140-339	FLAVOMYCIN / NICARB
NADA 140-340	STENOROL / LINCOMIX
NADA 140-533	STENOROL / 3-NITRO / BMD
NADA 140-584	STENOROL / BMD
NADA 140-824	STENOROL Type A medicated article
NADA 140-843	MONTEBAN / FLAVOMYCIN / 3-NITRO
NADA 140-845	FLAVOMYCIN / MONTEBAN
NADA 140-918	STENOROL / FLAVOMYCIN
NADA 140-919	STENOROL / BMD
NADA 141-034	GAINPRO (bambermycins) Type A medicated article
NADA 141-129	AVATEC / FLAVOMYCIN
ANADA 200-075	SACOX (salinomycin sodium) Type A medicated article
ANADA 200-080	SACOX / 3-NITRO / FLAVOMYCIN
ANADA 200-081	SACOX / 3-NITRO / BMD
ANADA 200-082	SACOX / BMD
ANADA 200-083	SACOX / FLAVOMYCIN
ANADA 200-086	SACOX / ALBAC / 3-NITRO
ANADA 200-089	SACOX / BACIFERM
ANADA 200-090	SACOX / LINCOMIX / 3-NITRO
ANADA 200-091	SACOX / 3-NITRO / AUREOMYCIN
ANADA 200-092	SACOX / STAFAC
ANADA 200-093	SACOX / LINCOMIX
ANADA 200-094	SACOX / STAFAC / 3-NITRO

Application No.	Trade Name(s)
ANADA 200-095	SACOX / AUREOMYCIN
ANADA 200-096	SACOX / TERRAMYCIN
ANADA 200-097	SACOX / 3-NITRO
ANADA 200-143	SACOX / 3-NITRO / BACIFERM

Accordingly, the agency is amending the regulations in 21 CFR 558.55, 558.58, 558.95, 558.120, 558.265, 558.311, 558.355, 558.363, 558.366, 558.450, 558.550, and 558.680 to reflect the transfer of ownership and a current format.

In addition, Huvepharma AD has not been previously listed in the animal drug regulations as a sponsor of an approved application. At this time, 21 CFR 510.600(c) is being amended to add entries for the firm.

Also, FDA has found that the April 1, 2005, edition of Title 21, parts 500 to 599 of the Code of Federal Regulations (CFR) does not accurately reflect the use limitations for amprolium in single-ingredient, medicated broiler chicken feeds. The existing entry erroneously includes limitations normally associated with the use of arsenicals in feed. At this time, the regulations are being amended in § 558.55 to correct this error. FDA is also taking this opportunity to consolidate entries for similar combination medicated feeds in the same section of part 558, and to eliminate duplicate entries. These actions are being taken to improve the accuracy and readability of the regulations.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

List of Subjects

21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

21 CFR Part 558

Animal drugs, Animal feeds.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 558 are amended as follows:

PART 510—NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 510 continues to read as follows:

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

■ 2. In § 510.600, in the table in paragraph (c)(1) alphabetically add an entry for “Huvepharma AD”; and in the table in paragraph (c)(2) numerically add an entry for “016592” to read as follows:

§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

* * * * *

(c) * * *

(1) * * *

Firm name and address	Drug labeler code
* * * *	* * *
Huvepharma AD, 33 James Boucher Blvd., Sophia 1407, Bulgaria	016592
* * * *	* * *

(2) * * *

Drug labeler code	Firm name and address
* * *	* * *
016592	Huvepharma AD, 33 James Boucher Blvd., Sophia 1407, Bulgaria
* * *	* * *

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

■ 3. The authority citation for 21 CFR part 558 continues to read as follows:

Authority: 21 U.S.C. 360b, 371.

§ 558.55 [Amended]

■ 4. Amend § 558.55 as follows:

■ a. In the table in paragraph (d)(2)(ii), in the “Limitations” column in the entry for “Amprolium 72.6 to 113.5 grams per ton”, remove the first sentence;

■ b. In the table in paragraph (d)(2)(iii), in the “Limitations” column in the entry for “Bambermycins 1 to 3 plus roxarsone 22.8 to 34.1 (0.0025% to 0.00375%)”, remove “057926” and add in its place “016592”; and in the “Sponsor” column add “016592” and

■ c. In the table in paragraph (d)(2)(iii), in the “Limitations” column and “Sponsor” column in the entry for

“Bambermycins 1 to 4”, remove “057926” and add in its place “016592”.

■ 5. Amend § 558.58 as follows:

- a. Revise paragraph (a);
- b. Redesignate paragraphs (b), (c), and (d) as paragraphs (c), (d), and (e);
- c. Add new paragraph (b);
- d. In the table in newly redesignated paragraph (e)(1)(i), add an entry for “Bambermycins 1 to 3 plus roxarsone 22.8 to 34.1”;
- e. In the table in newly redesignated paragraph (e)(1)(ii), in the “Limitations” column in the entries for

“Bambermycins 2 to 3 plus roxarsone 22.8 to 34.1”, remove “057926” and add in its place “016592”; and in the “Sponsor” column add “016592”; and

■ f. In the table in newly redesignated paragraph (e)(1)(iii), in the “Limitations” column in the entries for “Bambermycins 1 to 3” and “Bambermycins 1 to 3 plus roxarsone 22.8 to 34.1”, remove “057926” and add in its place “016592”; and in the “Sponsor” column add “016592”.

The revisions and additions read as follows:

§ 558.58 Amprolium and ethopabate.

(a) *Specifications.* Type A medicated articles containing:

- (1) 25 percent amprolium and 8 percent ethopabate or 5 percent amprolium and 1.6 percent ethopabate;
- (2) 25 percent amprolium and 0.8 percent ethopabate or 5 percent amprolium and 0.16 percent ethopabate.

(b) *Approvals.* See No. 050604 in § 510.600(c) of this chapter.

* * * * *

(e) * * *

(1) * * *

Amprolium and ethopabate in grams per ton	Combination in grams per ton	Indications for use	Limitations	Sponsor
(i) Amprolium 113.5 (0.0125%) and ethopabate 3.6 (0.0004%).	* * *	* * *	*	*
	Bambermycins, 1 to 3; plus roxarsone, 22.8 to 34.1	Broiler chickens: As an aid in the prevention of coccidiosis; and for increased rate of weight gain, improved feed efficiency, and improved pigmentation.	Feed continuously as the sole ration; as sole source of amprolium and organic arsenic; withdraw 5 d before slaughter; roxarsone provided by No. 046573, bambermycins by No. 016592 in § 510.600(c) of this chapter.	016592
* * *	* * *	* * *	* * *	* * *

* * * * *

■ 6. Amend § 558.95 as follows:

- a. In paragraphs (a)(1), (a)(2), and (a)(5), remove “057926” and add in its place “016592”;
- b. Remove and reserve paragraph (d)(1)(ii);
- c. Remove paragraphs (d)(1)(iii) through (d)(1)(xiv) and paragraphs (d)(3)(iii) and (d)(3)(iv); and
- d. Revise paragraph (d)(5).

The revision reads as follows:

§ 558.95 Bambermycins.

* * * * *

(d) * * *

(5) Bambermycins may also be used in combination with:

- (i) Amprolium alone or with roxarsone as in § 558.55.
- (ii) Amprolium and ethopabate alone or with roxarsone as in § 558.58.
- (iii) Diclazuril as in § 558.198.
- (iv) Halofuginone as in § 558.265.
- (v) Lasalocid alone or with roxarsone as in § 558.311.
- (vi) Monensin alone or with roxarsone as in § 558.355.
- (vii) Narasin alone or with nicarbazin or roxarsone as in § 558.363.
- (viii) Nicarbazin as in § 558.366.
- (ix) Salinomycin alone or with roxarsone as in § 558.550.

(x) Zoalene alone or with roxarsone as in § 558.680.

- 7. In § 558.120, add paragraph (d)(1)(iv) and remove paragraph (d)(2)(iii) to read as follows:

§ 558.120 Carbarson (not U.S.P.).

* * * * *

(d) * * *

(1) * * *

(iv) *Grams per ton.* 227 carbarson, plus 1 or 4 grams per ton bambermycins.

(a) *Indications for use.* As an aid in the prevention of blackhead; and for increased rate of weight gain (4 grams per ton bambermycins) or improved feed efficiency (1 gram per ton bambermycins).

(b) *Limitations.* Feed continuously 2 weeks before blackhead is expected and continue as long as prevention is needed. Withdraw 5 days before slaughter. As sole source of organic arsenic. Bambermycins provided by No. 046573 in § 510.600(c) of this chapter.

* * * * *

- 8. In § 558.265, revise paragraph (a); redesignate paragraphs (b) and (c) as paragraphs (c) and (d); and add new paragraph (b) to read as follows:

§ 558.265 Halofuginone hydrobromide.

(a) *Specifications.* Type A medicated articles containing 6 grams of halofuginone hydrobromide per kilogram.

(b) *Approvals.* See No. 016592 in § 510.600(c) of this chapter.

* * * * *

■ 9. Amend § 558.311 as follows:

■ a. In the table in paragraph (e)(1)(ii) in the entry in the “Combination in grams per ton” column for “Roxarsone 45.4 plus bambermycins 1”, in the “Limitations” column remove “012799” and add in its place “016592”;

■ b. In the table in paragraph (e)(1)(ii) following the entry in the “Combination in grams per ton” column for “Roxarsone 45.4 plus bambermycins 1”, add an entry for “Bambermycins 1 to 2”; and

■ c. Remove and reserve paragraph (e)(5)(ii).

The addition reads as follows:

§ 558.311 Lasalocid.

* * * * *

(e) * * *

(1) * * *

Lasalocid in grams per ton	Combination in grams per ton	Indications for use	Limitations	Sponsor
*	*	*	*	*
(ii) 68 (0.0075 pct) to 113 (0.0125 pct).	*	*	*	
*	*	*	*	*
	Bambermycins 1 to 2	Broiler chickens: For prevention of coccidiosis caused by <i>Eimeria tenella</i> , <i>E. necatrix</i> , <i>E. acervulina</i> , <i>E. brunetti</i> , <i>E. mivati</i> , and <i>E. maxima</i> ; and for increased rate of weight gain and improved feed efficiency.	Feed continuously as sole ration. Bambermycins provided by No. 016592 in § 510.600(c) of this chapter.	016592
*	*	*	*	*

* * * * *

■ 10. In § 558.355, in paragraphs (b)(10), (f)(2)(v)(b), and (f)(2)(vi)(b), remove “057926” and add in its place “016592”; and revise paragraphs (f)(1)(vi), (f)(1)(vii), and (f)(1)(xvii) to read as follows:

§ 558.355 Monensin.

* * * * *

(f) * * *

(1) * * *

(vi) *Amount per ton.* Monensin, 90 to 110 grams; plus bambermycins, 1 to 2 grams.

(a) *Indications for use.* For increased rate of weight gain and improved feed efficiency; and as an aid in the prevention of coccidiosis caused by *E. necatrix*, *E. tenella*, *E. acervulina*, *E. brunetti*, *E. mivati*, and *E. maxima*.

(b) *Limitations.* Feed continuously as sole ration; do not feed to laying chickens. Bambermycins provided by No. 016592 in § 510.600(c) of this chapter.

(vii) *Amount per ton.* Monensin, 90 to 110 grams; plus bambermycins, 1 gram; plus roxarsone, 22.7 to 45.4 grams

(a) *Indications for use.* For increased rate of weight gain and improved feed

efficiency; and as an aid in the prevention of coccidiosis caused by *E. necatrix*, *E. tenella*, *E. acervulina*, *E. brunetti*, *E. mivati*, and *E. maxima*.

(b) *Limitations.* Feed continuously as sole ration; use as sole source of organic arsenic; withdraw 5 d before slaughter; do not feed to laying chickens. Bambermycins provided by No. 016592 in § 510.600(c) of this chapter; roxarsone provided by No. 046573.

* * * * *

(xvii) *Amount per ton.*

Bambermycins, 1 to 2 grams plus monensin, 90 to 110 grams plus roxarsone, 22.7 to 45.4 grams.

(a) *Indications for use.* For increased rate of weight gain; and as an aid in prevention of coccidiosis caused by *E. necatrix*, *E. tenella*, *E. acervulina*, *E. brunetti*, *E. mivati*, and *E. maxima*.

(b) *Limitations.* Feed continuously as sole ration; use as sole source of organic arsenic; withdraw 5 d before slaughter; do not feed to laying chickens. Bambermycins provided by No. 016592 in § 510.600(c) of this chapter; roxarsone provided by No. 046573.

* * * * *

■ 11. Amend § 558.363 as follows:

■ a. In paragraphs (a)(4), (a)(5), and (d)(1)(vii)(B), remove “057926” and add in its place “016592”;

■ b. In paragraph (d)(1)(iv)(B) add a new sentence at the end of the paragraph; and

■ c. Remove paragraph (d)(1)(xii).

The addition reads as follows:

§ 558.363 Narasin.

* * * * *

(d) * * *

(1) * * *

(iv) * * *

(B) * * * Narasin as provided by No. 000986; bambermycins by No. 016592 in § 510.600(c) of this chapter.

* * * * *

■ 12. In the table in paragraph (d) of § 558.366, alphabetically add new entries for “Narasin 27 to 45, and bambermycins 1 to 2” and “Bambermycins 1 to 2” to read as follows:

§ 558.366 Nicarbazine.

* * * * *

(d) * * *

Nicarbazine in grams per ton	Combination in grams per ton	Indications for use	Limitations	Sponsor
*	*	*	*	*
	Narasin 27 to 45, and bacitracin methylene disalicylate 50, and roxarsone 22.7 to 45.4	*	*	*

Nicarbazin in grams per ton	Combination in grams per ton	Indications for use	Limitations	Sponsor
	Narasin 27 to 45, and bambermycins 1 to 2	Broiler chickens: As an aid in preventing outbreaks of cecal (<i>Eimeria tenella</i>) and intestinal (<i>E. acervulina</i> , <i>E. maxima</i> , <i>E. necatrix</i> , and <i>E. brunetti</i>) coccidiosis; and for increased rate of weight gain and improved feed efficiency.	Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard; do not use as a treatment for coccidiosis; do not use in flushing mashers; do not feed to laying hens; withdraw 4 days before slaughter. Bambermycins provided by No. 016592; nicarbazin and narasin by No. 066104 in § 510.600(c) of this chapter..	000986
*	*	*	*	*
113.5 (0.0125 pct)	*	*	*	*
	Bacitracin zinc 4 to 50	*	*	*
	Bambersmycins 1 to 2	Broiler chickens: For prevention of coccidiosis caused by <i>Eimeria tenella</i> , <i>E. necatrix</i> , <i>E. acervulina</i> , <i>E. brunetti</i> , <i>E. mivati</i> , and <i>E. maxima</i> ; and for increased rate of weight gain and improved feed efficiency.	Feed continuously as sole ration. Bambersmycins provided by No. 016592 in § 510.600(c) of this chapter.	016592
*	*	*	*	*

■ 13. In the table in paragraph (d)(1)(vii) of § 558.450, remove the entry for “Salinomycin 40 to 60 g/ton”; and add paragraph (d)(3)(v) to read as follows:

§ 558.450 Oxytetracycline.

* * * * *

(d) * * *

(3) * * *

(v) Salinomycin as in § 558.550.

■ 14. In § 558.550, in paragraphs (d)(1)(xv)(c) and (d)(1)(xvi)(c), remove “057926” and add in its place “016592”; add paragraphs (d)(1)(xxiii) and (d)(1)(xxiv); and revise paragraphs (b)(2) and (d)(4) to read as follows:

§ 558.550 Salinomycin.

* * * * *

(b) * * *

(2) No. 016592 for use as in paragraphs (d)(1)(i), (d)(1)(iii) through (d)(1)(xvi), (d)(1)(xxiii) and (d)(1)(xxiv), (d)(2)(i), (d)(3)(i), and (d)(4) of this section.

* * * * *

(d) * * *

(1) * * *

(xxiii) *Amount per ton.* Salinomycin, 40 to 60 grams; plus bambersmycins, 1 to 3 grams.

(a) *Indications for use.* Broiler chickens: For prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*,

and *E. mivati*; and for improved feed efficiency.

(b) *Limitations.* Feed continuously as sole ration. Do not feed to laying chickens; not approved for use with pellet binders; may be fatal if accidentally fed to adult turkeys or horses. Salinomycin as provided by Nos. 046573 and 016592; bambersmycins by No. 016592 in § 510.600(c) of this chapter.

(xxiv) *Amount per ton.* Salinomycin, 40 to 60 grams; plus bambersmycins, 1 to 2 grams; plus roxarsone, 45.4 grams.

(a) *Indications for use.* Broiler chickens: For prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati*, including some field strains of *E. tenella* that are more susceptible to roxarsone combined with salinomycin than salinomycin alone; and for improved feed efficiency.

(b) *Limitations.* Feed continuously as sole ration. Do not feed to laying chickens; as sole source or organic arsenic; withdraw 5 days before slaughter; not approved for use with pellet binders; may be fatal if accidentally fed to adult turkeys or horses; Salinomycin as provided by Nos. 046573 and 016592; bambersmycins by No. 016592; roxarsone by No. 046573 in § 510.600(c) of this chapter.

* * * * *

(4) *Chickens:* It is used in chicken feed as follows:

(i) *Amount per ton.* Salinomycin, 40 to 60 grams; plus oxytetracycline, 500 grams.

(a) *Indications for use.* For prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati*; and for reduction of mortality due to air sacculitis (air-sac-infection) caused by *Escherichia coli* susceptible to oxytetracycline.

(b) *Limitations.* Feed continuously for 5 days; do not feed to chickens producing eggs for human consumption; withdraw 24 hours before slaughter; in low calcium feeds withdraw 3 d before slaughter. Salinomycin as provided by Nos. 046573 and 016592; oxytetracycline as provided by No. 066104 in § 510.600(c) of this chapter.

(ii) [Reserved]

■ 15. In § 558.680, alphabetically add two entries to the table in paragraph (d)(1)(ii); and revise paragraph (d)(2) to read as follows:

§ 558.680 Zoalene.

* * * * *

(d) * * *

(1) * * *

Zoalene in grams per ton	Combination in grams per ton	Indications for use	Limitations
(ii) 113.5 (0.0125%).	* *	* *	* *
	Bacitracin 100 to 500	* *	* *
	Bambermycins 1	Broiler chickens: As an aid in the prevention and control of coccidiosis; and for increased rate of weight gain and improved feed efficiency.	Feed continuously as sole ration. Do not feed to chickens over 14 weeks of age. Bambermycins as provided by No. 016592 in § 510.600(c) of this chapter.
	Bambermycins 1 plus roxarsone 22.7	Broiler chickens: As an aid in the prevention and control of coccidiosis; and for increased rate of weight gain and improved feed efficiency.	Feed continuously as sole ration. Do not feed to chickens over 14 weeks of age; feed as sole source of organic arsenic; withdraw 5 days before slaughter. Bambermycins as provided by No. 016592, roxarsone by No. 046573 in § 510.600(c) of this chapter.
* *	* *	* *	* *

(2) Zoalene may also be used in combination with roxarsone as in § 558.530.

Dated: May 3, 2006.

Steven D. Vaughn,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 06-4505 Filed 5-12-06; 8:45 am]

BILLING CODE 4160-01-S

PENSION BENEFIT GUARANTY CORPORATION

29 CFR Parts 4022 and 4044

Benefits Payable in Terminated Single-Employer Plans; Allocation of Assets in Single-Employer Plans; Interest Assumptions for Valuing and Paying Benefits

AGENCY: Pension Benefit Guaranty Corporation.

ACTION: Final rule.

SUMMARY: The Pension Benefit Guaranty Corporation's regulations on Benefits Payable in Terminated Single-Employer Plans and Allocation of Assets in Single-Employer Plans prescribe interest assumptions for valuing and paying benefits under terminating single-employer plans. This final rule amends the regulations to adopt interest assumptions for plans with valuation dates in June 2006. Interest assumptions are also published on the PBGC's Web site (<http://www.pbgc.gov>).

DATES: Effective June 1, 2006.

FOR FURTHER INFORMATION CONTACT: Catherine B. Klion, Attorney, Legislative and Regulatory Department, Pension Benefit Guaranty Corporation, 1200 K

Street, NW., Washington, DC 20005, 202-326-4024. (TTY/TDD users may call the Federal relay service toll-free at 1-800-877-8339 and ask to be connected to 202-326-4024.)

SUPPLEMENTARY INFORMATION: The PBGC's regulations prescribe actuarial assumptions—including interest assumptions—for valuing and paying plan benefits of terminating single-employer plans covered by title IV of the Employee Retirement Income Security Act of 1974. The interest assumptions are intended to reflect current conditions in the financial and annuity markets.

Three sets of interest assumptions are prescribed: (1) A set for the valuation of benefits for allocation purposes under section 4044 (found in appendix B to part 4044), (2) a set for the PBGC to use to determine whether a benefit is payable as a lump sum and to determine lump-sum amounts to be paid by the PBGC (found in appendix B to part 4022), and (3) a set for private-sector pension practitioners to refer to if they wish to use lump-sum interest rates determined using the PBGC's historical methodology (found in appendix C to part 4022).

This amendment (1) adds to appendix B to part 4044 the interest assumptions for valuing benefits for allocation purposes in plans with valuation dates during June 2006, (2) adds to appendix B to part 4022 the interest assumptions for the PBGC to use for its own lump-sum payments in plans with valuation dates during June 2006, and (3) adds to appendix C to part 4022 the interest assumptions for private-sector pension practitioners to refer to if they wish to

use lump-sum interest rates determined using the PBGC's historical methodology for valuation dates during June 2006.

For valuation of benefits for allocation purposes, the interest assumptions that the PBGC will use (set forth in appendix B to part 4044) will be 6.20 percent for the first 20 years following the valuation date and 4.75 percent thereafter. These interest assumptions represent an increase (from those in effect for May 2006) of 0.30 percent for the first 20 years following the valuation date and are otherwise unchanged. These interest assumptions reflect the PBGC's recently updated mortality assumptions, which are effective for terminations on or after January 1, 2006. See the PBGC's final rule published December 2, 2005 (70 FR 72205), which is available at <http://www.pbgc.gov/docs/05-23554.pdf>. Because the updated mortality assumptions reflect improvements in mortality, these interest assumptions are higher than they would have been using the old mortality assumptions.

The interest assumptions that the PBGC will use for its own lump-sum payments (set forth in Appendix B to part 4022) will be 3.25 percent for the period during which a benefit is in pay status and 4.00 percent during any years preceding the benefit's placement in pay status. These interest assumptions represent an increase (from those in effect for May 2006) of 0.25 percent for the period during which a benefit is in pay status and are otherwise unchanged.

For private-sector payments, the interest assumptions (set forth in Appendix C to part 4022) will be the same as those used by the PBGC for